Nuveen, LLC
"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.
13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.
This manager has only 0 evaluable quarters in its current filing history, below our eight-quarter minimum. The holdings and AUM below are current, but we do not assign a copy-trading verdict until enough post-publication returns exist.
Quarterly compounding, invested quarters only · entry after the actual SEC deadline plus a 2-day buffer
Top 20 holdings of 3735 · 2026 Q2
| Ticker | Value | Weight | QoQ |
|---|---|---|---|
| NVDA | $26.9B | | TRIM −4% |
| AAPL | $21.7B | | TRIM −5% |
| MSFT | $15.1B | | TRIM −9% |
| AVGO | $12.8B | | TRIM −7% |
| AMZN | $11.7B | | TRIM −14% |
| GOOGL | $11.4B | | ADD +4% |
| GOOG | $11.1B | | HOLD |
| TSLA | $6.7B | | ADD +18% |
| LLY | $6.1B | | TRIM −5% |
| META | $5.4B | | TRIM −7% |
| JPM | $4.7B | | TRIM −5% |
| MU | $4.6B | | ADD +21% |
| AMAT | $4.4B | | HOLD |
| LRCX | $4.0B | | TRIM −16% |
| AMD | $3.9B | | ADD +4% |
| INTC | $3.6B | | TRIM −20% |
| MA | $3.6B | | TRIM −15% |
| JNJ | $3.3B | | ADD +4% |
| PANW | $3.1B | | ADD +13% |
| COST | $3.0B | | ADD +4% |
QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.
New positions in 2026 Q2
Method & Limitations
Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry is the first trading session after the actual SEC filing deadline plus a 2-day buffer. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.